About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Monthly Archives: October 2006
Lettuce Beware
Let’s face it, it has been a bad season for vegetables. To date, there have been 199 cases of E coli from spinach in 26 states. Each day, the FDA has been issuing spinach status updates on the situation which … Continue reading
Posted in Current Affairs, FDA Image, Food
Comments Off on Lettuce Beware
Synopsis of the Congressional Budget Office Report on the Future of Pharmaceuticals
On Friday, I mentioned that last week the Congressional Budget Office issued a report entitled "Research and Development in the Pharmaceutical Industry". Over the weekend, I got to read the 65-page report in detail and found it quite interesting. The … Continue reading
Posted in Current Affairs
Comments Off on Synopsis of the Congressional Budget Office Report on the Future of Pharmaceuticals
Weekly Roundup 10-6-06
Alas, where has the week gone to? It is time for the weekly round up. As scandal breaks in our nation’s city, and the Congress is in a scramble right at election time, we inside the Beltway are wondering what … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 10-6-06
Warning Letter Summary for Third Quarter 2006
The rate of Warning Letters coming from DDMAC for violations by pharmaceutical companies continues to come out a slow-paced drip. The third quarter of 2006 produced only four letters from DDMAC for communications issues. DDMAC reviews all types of communications … Continue reading
Posted in Uncategorized
Comments Off on Warning Letter Summary for Third Quarter 2006
A Study of Statins
There is perhaps no better candidate in the pipeline for an RX to OTC switch than for statins. Statins lower cholesterol dramatically and therefore one can intuit – they would lower the rate of heart disease in this country if … Continue reading
Posted in OTC Switches
Comments Off on A Study of Statins